

Fiona H Marshall

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6549685/publications.pdf>

Version: 2024-02-01

90
papers

12,507
citations

28274

55
h-index

49909

87
g-index

91
all docs

91
docs citations

91
times ranked

11985
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | The Orphan G Protein-coupled Receptors GPR41 and GPR43 Are Activated by Propionate and Other Short Chain Carboxylic Acids. <i>Journal of Biological Chemistry</i> , 2003, 278, 11312-11319. | 3.4 | 1,866 |
| 2 | Heterodimerization is required for the formation of a functional GABAB receptor. <i>Nature</i> , 1998, 396, 679-682. | 27.8 | 1,104 |
| 3 | International Union of Pharmacology. XXXIII. Mammalian gamma -Aminobutyric AcidB Receptors: Structure and Function. <i>Pharmacological Reviews</i> , 2002, 54, 247-264. | 16.0 | 523 |
| 4 | Structure of the Adenosine A2A Receptor in Complex with ZM241385 and the Xanthines XAC and Caffeine. <i>Structure</i> , 2011, 19, 1283-1293. | 3.3 | 505 |
| 5 | Molecular Identification of High and Low Affinity Receptors for Nicotinic Acid. <i>Journal of Biological Chemistry</i> , 2003, 278, 9869-9874. | 3.4 | 473 |
| 6 | Generic GPCR residue numbers â€œ aligning topology maps while minding the gaps. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 22-31. | 8.7 | 387 |
| 7 | Structure of class B GPCR corticotropin-releasing factor receptor 1. <i>Nature</i> , 2013, 499, 438-443. | 27.8 | 378 |
| 8 | Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain. <i>Nature</i> , 2014, 511, 557-562. | 27.8 | 378 |
| 9 | GABAB receptors â€œ the first 7TM heterodimers. <i>Trends in Pharmacological Sciences</i> , 1999, 20, 396-399. | 8.7 | 324 |
| 10 | Discovery of 1,2,4-Triazine Derivatives as Adenosine A_{2A} Antagonists using Structure Based Drug Design. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 1898-1903. | 6.4 | 296 |
| 11 | Insights into the structure of class B GPCRs. <i>Trends in Pharmacological Sciences</i> , 2014, 35, 12-22. | 8.7 | 218 |
| 12 | CB1 and CB2 cannabinoid receptors are implicated in inflammatory pain. <i>Pain</i> , 2002, 96, 253-260. | 4.2 | 213 |
| 13 | Progress in Structure Based Drug Design for G Protein-Coupled Receptors. <i>Journal of Medicinal Chemistry</i> , 2011, 54, 4283-4311. | 6.4 | 203 |
| 14 | A Bioluminescent Assay for Agonist Activity at Potentially Any G-Protein-Coupled Receptor. <i>Analytical Biochemistry</i> , 1997, 252, 115-126. | 2.4 | 201 |
| 15 | Intracellular allosteric antagonism of the CCR9 receptor. <i>Nature</i> , 2016, 540, 462-465. | 27.8 | 192 |
| 16 | Structural insight into allosteric modulation of protease-activated receptor 2. <i>Nature</i> , 2017, 545, 112-115. | 27.8 | 192 |
| 17 | Extra-helical binding site of a glucagon receptor antagonist. <i>Nature</i> , 2016, 533, 274-277. | 27.8 | 190 |
| 18 | Structures of Human A 1 and A 2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. <i>Structure</i> , 2017, 25, 1275-1285.e4. | 3.3 | 178 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 19 | The GABAB receptor interacts directly with the related transcription factors CREB2 and ATFx. Proceedings of the National Academy of Sciences of the United States of America, 2000, 97, 13967-13972. | 7.1 | 166 |
| 20 | New insights from structural biology into the druggability of G protein-coupled receptors. Trends in Pharmacological Sciences, 2012, 33, 249-260. | 8.7 | 158 |
| 21 | Biophysical Fragment Screening of the β_1 -Adrenergic Receptor: Identification of High Affinity Arylpiperazine Leads Using Structure-Based Drug Design. Journal of Medicinal Chemistry, 2013, 56, 3446-3455. | 6.4 | 155 |
| 22 | Crystal structure of the GLP-1 receptor bound to a peptide agonist. Nature, 2017, 546, 254-258. | 27.8 | 155 |
| 23 | Controlling the Dissociation of Ligands from the Adenosine A _{2A} Receptor through Modulation of Salt Bridge Strength. Journal of Medicinal Chemistry, 2016, 59, 6470-6479. | 6.4 | 151 |
| 24 | Fragment and Structure-Based Drug Discovery for a Class C GPCR: Discovery of the mGlu ₅ Negative Allosteric Modulator HTL14242 (3-Chloro-5-[6-(5-fluoropyridin-2-yl)pyrimidin-4-yl]benzonitrile). Journal of Medicinal Chemistry, 2015, 58, 6653-6664. | 6.4 | 150 |
| 25 | The properties of thermostabilised G protein-coupled receptors (StaRs) and their use in drug discovery. Neuropharmacology, 2011, 60, 36-44. | 4.1 | 148 |
| 26 | Therapeutic antibodies directed at G protein-coupled receptors. MAbs, 2010, 2, 594-606. | 5.2 | 143 |
| 27 | RAMPs: accessory proteins for seven transmembrane domain receptors. Trends in Pharmacological Sciences, 1999, 20, 184-187. | 8.7 | 142 |
| 28 | Identification of Novel Adenosine A _{2A} Receptor Antagonists by Virtual Screening. Journal of Medicinal Chemistry, 2012, 55, 1904-1909. | 6.4 | 131 |
| 29 | Opportunities for therapeutic antibodies directed at G-protein-coupled receptors. Nature Reviews Drug Discovery, 2017, 16, 787-810. | 46.4 | 125 |
| 30 | The impact of GPCR structures on pharmacology and structure-based drug design. British Journal of Pharmacology, 2010, 159, 986-996. | 5.4 | 123 |
| 31 | Structures of G protein-coupled receptors reveal new opportunities for drug discovery. Drug Discovery Today, 2015, 20, 1355-1364. | 6.4 | 120 |
| 32 | G16 as a universal G protein adapter: implications for agonist screening strategies. Trends in Pharmacological Sciences, 1996, 17, 235-237. | 8.7 | 114 |
| 33 | Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727. Nature, 2018, 553, 111-114. | 27.8 | 110 |
| 34 | Biophysical Mapping of the Adenosine A _{2A} Receptor. Journal of Medicinal Chemistry, 2011, 54, 4312-4323. | 6.4 | 107 |
| 35 | Applying Structure-Based Drug Design Approaches to Allosteric Modulators of GPCRs. Trends in Pharmacological Sciences, 2017, 38, 837-847. | 8.7 | 106 |
| 36 | Protein-Protein Interaction and Not Glycosylation Determines the Binding Selectivity of Heterodimers between the Calcitonin Receptor-like Receptor and the Receptor Activity-modifying Proteins. Journal of Biological Chemistry, 2001, 276, 29575-29581. | 3.4 | 103 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Fragment Screening of Stabilized G-Protein-Coupled Receptors Using Biophysical Methods. <i>Methods in Enzymology</i> , 2011, 493, 115-136. | 1.0 | 103 |
| 38 | Structure of <i>C₁ class B GPCRs</i> : new horizons for drug discovery. <i>British Journal of Pharmacology</i> , 2014, 171, 3132-3145. | 5.4 | 96 |
| 39 | Advances in the molecular understanding of GABAB receptors. <i>Trends in Neurosciences</i> , 2001, 24, 277-282. | 8.6 | 90 |
| 40 | Calcium sensing properties of the GABAB receptor. <i>Neuropharmacology</i> , 1999, 38, 1647-1656. | 4.1 | 83 |
| 41 | Effects of amphetamine isomers, methylphenidate and atomoxetine on synaptosomal and synaptic vesicle accumulation and release of dopamine and noradrenaline in vitro in the rat brain. <i>Neuropharmacology</i> , 2007, 52, 405-414. | 4.1 | 83 |
| 42 | From G Protein-coupled Receptor Structure Resolution to Rational Drug Design. <i>Journal of Biological Chemistry</i> , 2015, 290, 19489-19495. | 3.4 | 81 |
| 43 | Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A _{2A} Receptor crystals. <i>Scientific Reports</i> , 2018, 8, 41. | 3.3 | 79 |
| 44 | Fragment Screening of GPCRs Using Biophysical Methods: Identification of Ligands of the Adenosine A _{2A} Receptor with Novel Biological Activity. <i>ACS Chemical Biology</i> , 2012, 7, 2064-2073. | 3.4 | 77 |
| 45 | The pharmacology of GR203040, a novel, potent and selective non-peptide tachykinin NK ₁ receptor antagonist. <i>British Journal of Pharmacology</i> , 1995, 116, 3149-3157. | 5.4 | 73 |
| 46 | High end GPCR design: crafted ligand design and druggability analysis using protein structure, lipophilic hotspots and explicit water networks. <i>In Silico Pharmacology</i> , 2013, 1, . | 3.3 | 72 |
| 47 | Pharmacological profile of GR117289 <i>in vitro</i> : a novel, potent and specific non-peptide angiotensin AT ₁ receptor antagonist. <i>British Journal of Pharmacology</i> , 1992, 107, 1173-1180. | 5.4 | 71 |
| 48 | Pharmacology and Structure of Isolated Conformations of the Adenosine A _{2A} Receptor Define Ligand Efficacy. <i>Molecular Pharmacology</i> , 2013, 83, 949-958. | 2.3 | 69 |
| 49 | GABAB receptor heterodimer-component localisation in human brain. <i>Molecular Brain Research</i> , 2000, 77, 111-124. | 2.3 | 67 |
| 50 | Cellular and sub-cellular localisation of GABAB1 and GABAB2 receptor proteins in the rat cerebellum. <i>Molecular Brain Research</i> , 2000, 83, 72-80. | 2.3 | 67 |
| 51 | Structure-Based Optimization Strategies for G Protein-Coupled Receptor (GPCR) Allosteric Modulators: A Case Study from Analyses of New Metabotropic Glutamate Receptor 5 (mGlu ₅) X-ray Structures. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 207-222. | 6.4 | 67 |
| 52 | Biacore analysis with stabilized G-protein-coupled receptors. <i>Analytical Biochemistry</i> , 2011, 409, 267-272. | 2.4 | 66 |
| 53 | Structurally Enabled Discovery of Adenosine A _{2A} Receptor Antagonists. <i>Chemical Reviews</i> , 2017, 117, 21-37. | 47.7 | 64 |
| 54 | Structure-Based Drug Design for G Protein-Coupled Receptors. <i>Progress in Medicinal Chemistry</i> , 2014, 53, 1-63. | 10.4 | 62 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Binding kinetics differentiates functional antagonism of orexinâ€² receptor ligands. <i>British Journal of Pharmacology</i> , 2014, 171, 351-363. | 5.4 | 55 |
| 56 | Activity of diadenosine polyphosphates at P2Y receptors stably expressed in 1321N1 cells. <i>European Journal of Pharmacology</i> , 2001, 430, 203-210. | 3.5 | 54 |
| 57 | Comparison of Orexin 1 and Orexin 2 Ligand Binding Modes Using X-ray Crystallography and Computational Analysis. <i>Journal of Medicinal Chemistry</i> , 2020, 63, 1528-1543. | 6.4 | 46 |
| 58 | Heterodimerization of G-protein-coupled receptors in the CNS. <i>Current Opinion in Pharmacology</i> , 2001, 1, 40-44. | 3.5 | 45 |
| 59 | From structure to clinic: Design of a muscarinic M1 receptor agonist with the potential to treat Alzheimerâ€™s disease. <i>Cell</i> , 2021, 184, 5886-5901.e22. | 28.9 | 44 |
| 60 | Development of Tolerance in Mice to the Sedative Effects of the Neuroactive Steroid Minaxolone Following Chronic Exposure. <i>Pharmacology Biochemistry and Behavior</i> , 1997, 58, 1-8. | 2.9 | 43 |
| 61 | Characterization of [3 H]-CGP54626A binding to heterodimeric GABAB receptors stably expressed in mammalian cells. <i>British Journal of Pharmacology</i> , 2000, 131, 1766-1774. | 5.4 | 41 |
| 62 | The Use of GPCR Structures in Drug Design. <i>Advances in Pharmacology</i> , 2011, 62, 1-36. | 2.0 | 38 |
| 63 | Selective Negative Allosteric Modulation Of Metabotropic Glutamate Receptors â€“ A Structural Perspective of Ligands and Mutants. <i>Scientific Reports</i> , 2015, 5, 13869. | 3.3 | 38 |
| 64 | Guanfacine produces differential effects in frontal cortex compared with striatum: assessed by pHMRI BOLD contrast. <i>Psychopharmacology</i> , 2006, 189, 369-385. | 3.1 | 36 |
| 65 | Atomoxetine produces changes in cortico-basal thalamic loop circuits: Assessed by pHMRI BOLD contrast. <i>Neuropharmacology</i> , 2007, 52, 812-826. | 4.1 | 36 |
| 66 | GPCR structure, function, drug discovery and crystallography: report from Academia-Industry International Conference (UK Royal Society) Chicheley Hall, 1â€²2 September 2014. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2015, 388, 883-903. | 3.0 | 34 |
| 67 | Is the GABA_B Heterodimer a Good Drug Target?. <i>Journal of Molecular Neuroscience</i> , 2005, 26, 169-176. | 2.3 | 33 |
| 68 | GABAB receptor subunits, R1 and R2, in brainstem catecholamine and serotonin neurons. <i>Brain Research</i> , 2003, 970, 35-46. | 2.2 | 32 |
| 69 | DIGESTIVE PHYSIOLOGY OF THE PIG SYMPOSIUM: Gut chemosensing and the regulation of nutrient absorption and energy supply1. <i>Journal of Animal Science</i> , 2013, 91, 1932-1945. | 0.5 | 32 |
| 70 | Monoclonal anti-Î²1-adrenergic receptor antibodies activate G protein signaling in the absence of Î²-arrestin recruitment. <i>MABs</i> , 2014, 6, 246-261. | 5.2 | 31 |
| 71 | Structures of mGluRs shed light on the challenges of drug development of allosteric modulators. <i>Current Opinion in Pharmacology</i> , 2015, 20, 1-7. | 3.5 | 29 |
| 72 | Decoding Corticotropin-Releasing Factor Receptor Type 1 Crystal Structures. <i>Current Molecular Pharmacology</i> , 2017, 10, 334-344. | 1.5 | 25 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 73 | Characterization of [³ H]prostaglandin E ₂ binding to prostaglandin EP ₄ receptors expressed with Semliki Forest virus. <i>British Journal of Pharmacology</i> , 1997, 121, 1673-1678. | 5.4 | 21 |
| 74 | Differential effects of the d- and l- isomers of amphetamine on pharmacological MRI BOLD contrast in the rat. <i>Psychopharmacology</i> , 2007, 193, 11-30. | 3.1 | 20 |
| 75 | Heterodimerization of the GABAB Receptor—Implications for GPCR Signaling and Drug Discovery. <i>Advances in Pharmacology</i> , 2010, 58, 63-91. | 2.0 | 20 |
| 76 | Studies of a ubiquitous receptor family. <i>Nature</i> , 2012, 492, 57-57. | 27.8 | 18 |
| 77 | The Role of GABAB Receptors in the Regulation of Excitatory Neurotransmission. , 2008, 44, 87-98. | | 16 |
| 78 | Mapping the central effects of methylphenidate in the rat using pharmacological MRI BOLD contrast. <i>Neuropharmacology</i> , 2009, 57, 653-664. | 4.1 | 15 |
| 79 | Conformational thermostabilisation of corticotropin releasing factor receptor 1. <i>Scientific Reports</i> , 2015, 5, 11954. | 3.3 | 15 |
| 80 | Discovery of HTL6641, a dual orexin receptor antagonist with differentiated pharmacodynamic properties. <i>MedChemComm</i> , 2015, 6, 947-955. | 3.4 | 15 |
| 81 | Binding of angiotensin antagonists to rat liver and brain membranes measured <i>ex vivo</i> . <i>British Journal of Pharmacology</i> , 1993, 109, 760-764. | 5.4 | 13 |
| 82 | Purification of Stabilized GPCRs for Structural and Biophysical Analyses. <i>Methods in Molecular Biology</i> , 2015, 1335, 1-15. | 0.9 | 12 |
| 83 | Preparation of purified GPCRs for structural studies. <i>Biochemical Society Transactions</i> , 2013, 41, 185-190. | 3.4 | 11 |
| 84 | Heterodimerization of β -aminobutyric acid B receptor subunits as revealed by the yeast two-hybrid system. <i>Methods</i> , 2002, 27, 301-310. | 3.8 | 10 |
| 85 | Temperature and agonist dependency of tachykinin NK1 receptor antagonist potencies in rat isolated superior cervical ganglion. <i>European Journal of Pharmacology</i> , 1995, 294, 163-171. | 3.5 | 9 |
| 86 | Visualizing GPCR "Megaplexes"™ Which Enable Sustained Intracellular Signaling. <i>Trends in Biochemical Sciences</i> , 2016, 41, 985-986. | 7.5 | 9 |
| 87 | Implications of metabotropic glutamate receptor structures for drug discovery in neurotherapeutics. <i>Expert Review of Neurotherapeutics</i> , 2015, 15, 123-125. | 2.8 | 7 |
| 88 | Identification of a novel allosteric GLP-1R antagonist HTL26119 using structure-based drug design. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2019, 29, 126611. | 2.2 | 5 |
| 89 | Heterodimerisation of GABAB receptors. <i>Biochemical Society Transactions</i> , 1999, 27, A70-A70. | 3.4 | 0 |
| 90 | A Summary and Conclusions From the Meeting. <i>Journal of Molecular Neuroscience</i> , 2005, 26, 295-298. | 2.3 | 0 |